Abstract: Methods of making and using E,Z,E-GGPP are provided. Also provided are expression cassettes encoding isoprenyl diphosphate synthases, e.g., cis- or trans-isoprenyl diphosphate synthases.

Abstract: Materials are disclosed for the safe sequestration and removal of hazardous contaminants from a surface. The materials can be sprayed, rolled, painted, brushed or dip coated onto any surface and allowed to dry and/or cure at room temperature or drying/curing can be accelerated by the application of heat to form a coating that entraps the contaminant therein. The coating and the entrapped contaminant can then peeled from the surface and safely disposed of to minimize hazardous waste. The coating includes a colorimetric additive that is specific to the contaminant, the coating and the contaminant producing a visual indication of contamination.

Abstract: Methods and systems for identifying a protein within a sample are provided herein. A panel of antibodies are acquired, none of which are specific for a single protein or family of proteins. Additionally, the binding properties of the antibodies in the panel are determined. Further, the protein is iteratively exposed to a panel of antibodies. Additionally, a set of antibodies which bind the protein are determined. The identity of the protein is determined using one or more deconvolution methods based on the known binding properties of the antibodies to match the set of antibodies to a sequence of a protein.

Abstract: The disclosed invention is related to a universal strand-specific protocol for the sequencing preparation of all classes of RNA. The protocol allows for sequencing for dozens to more than thousands of samples simultaneously. Specifically, the disclosed invention is a method for parallel sequencing target RNA from samples from multiple sources while maintaining source identification.

Abstract: A method for detecting phospholipase D (PLD) activity in a cell, comprising: (i) stimulating endogenous PLD in said cell for said PLD to catalyze a transphosphatidylation reaction between phosphatidylcholine or a derivative thereof and an exogenous functionalized alcohol to form a phosphatidyl alcohol, wherein the functionalized alcohol possesses a first functional group that can react with and form a bond to a functionalized detectable label having a second functional group reactive with the first functional group, and said phosphatidyl alcohol contains said first functional group in available form; (ii) reacting said phosphatidyl alcohol with said functionalized detectable label under conditions where said functionalized detectable label reacts, via its second functional group, with the first functional group to form a linkage between said detectable label and said phosphatidyl alcohol so as to form a labeled phosphatidyl alcohol containing said detectable label; and (iii) detecting said labeled phosphatidy

Abstract: A reagent for glutamine synthetase reaction comprising a chelating agent and glutamine synthetase, and a reagent for quantification of ammonia comprising a chelating agent, ATP, glutamic acid, glutamine synthetase, glucose, an oxidized NAD compound, ADP-dependent hexokinase, and glucose-6-phosphate dehydrogenase, are provided.

Abstract: A method of producing a cDNA from a sample of nucleic acids includes the steps of: generating a dephosphorylated RNA from the sample; ligating the dephosphorylated RNA with a first adapter in the presence of a crowding agent to produce a ligated product; removing the excess first adapter by adding at least two enzymes; and performing reverse transcription in a lithium-containing buffer to produce the cDNA. A method of preparing a DNA library and a kit for such preparation are also disclosed.

Abstract: Chronotherapeutic dosing can include receiving, using a processor, sensor data from a sensor for a user, wherein the sensor data is collected subsequent to the user starting a regimen for a medication, determining, using the processor, a biological marker from the sensor data, wherein the biological marker is correlated with the medication, and comparing, using the processor, the biological marker with an expected state of the biological marker based upon a dose time of the medication. Chronotherapeutic dosing can also include providing, using the processor, a notification indicating a result of the comparing.

Abstract: A non-destructive testing and inspection (NDT/NDI) system having a communication gateway removably secured to an existing NDT/NDI instrument by a clip-on clasp. The gateway comprises a processor, a network interface, a housing configured to be removably secured onto the NDT/NDI instrument, an interconnect configured to be communicatively coupled with and to carry data to or from the NDT/NDI instrument, and memory storing computer readable code which, when executed on the processor, causes the processor to communicate data with an external network over the network interface. The data includes inspection data which can be any one of the following: ultrasonic scans of A, B, C or S, eddy current strip charts.

Abstract: The invention relates to a device and a method for automated evaluation of incubated immunoblot strips (5). What is essential for such immunoblot strips (5) is that these have regions coated with antigens, which regions discolour under the formation of so-called bands (6) as soon as a binding occurs, in particular between the antigen and an antibody present in a patient sample. Within the scope of the described technical solution, a camera (2) is initially used to make recordings of the surface of an incubated immunoblot strip (5) and these recordings are transmitted in digitized form to an evaluation unit (1). Finally, the discolourings, which occurred in the form of bands (6), are detected and at least partly quantified in the evaluation unit (1), such that a diagnosis suggestion is generated taking into account the number of bands (6) and the colour strength thereof.

Abstract: One or more live substances is cultured at a plurality of test locations of a test vessel. The test locations include a thermochromic material and one or more test substances. A spectral shift in light emanating from the thermochromic material of the test locations is detected. The spectral shift occurs in response to an increase or decrease in energy conversion by the live substance. An effect of the one or more test substances on the live substances is determined based on the detected spectral shift.

Abstract: A detection chip includes: a liquid container; and a light-transmitting substrate in which one of two surfaces facing each other faces an inside of the liquid container and an LSPR structure that generates localized surface plasmon resonance by light irradiation is disposed on the other surface of the two surfaces or in a region sandwiched between the one surface and the other surface.

Abstract: The present invention relates to an immunoassay method for the detection of Chromogranin A (or fragment(s) thereof) comprising the steps of contacting a sample suspected of comprising Chromogranin A with a first antibody or an antigen-binding fragment or derivative thereof specific for Chromogranin A and a second antibody or an antigen-binding fragment or derivative thereof specific for Chromogranin A under conditions allowing for the formation of a ternary complex between Chromogranin A and the two antibodies or antigen-binding fragments or derivates thereof, and detecting the binding of the two antibodies or antigen-binding fragments or derivates thereof to Chromogranin A. Also provided are antibodies directed against amino acid residues 124 to 144 and 280 to 301 of Chromogranin A and their use in the immunoassay method.

Abstract: A portable device for detecting an analyte associated with a target organic molecule in a liquid and/or solid substance. The device includes a test chamber, a probe, and a sensor. The test chamber contains a liquid volume of test solution including an analytical reagent selected to react with the analyte. The test chamber is sealed by a pierceable membrane wall. The probe is removably positionable to pierce the membrane wall to deposit a sample in the test chamber to form a test mixture with the test solution. The sensor is positioned to detect one or more characteristics of the test mixture in the test chamber indicative of a reaction between the analyte and the analytical reagent.

Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a AMPK activator to a subject in need thereof, wherein In certain embodiments, the AMPK activator is metformin or salt thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

Abstract: A slide processing apparatus controls the temperature and orientation of a microscope slide carrying one or more specimens. The apparatus heats the specimen-bearing microscope slide while the slide is oriented to both facilitate adhesion between the specimens and the slide and control movement of the specimens relative to the microscope slide. A slide dryer of the apparatus conductively heats the specimens using a conductive slide heater that physically engages the microscope slide.

Abstract: A novel peptide sequence that is a modified derivative of a neuron-specific tyrosine phosphatase is shown and described. Specifically, the novel peptide sequence is a modified derivative of striatal-enriched tyrosine phosphatase (STEP). The peptide sequence has been modified so as to be able to ameliorate and treat brain injury resulting from excessive glutamate release and/or oxidative stress. Examples of the types of brain injury which the presently disclosed peptide sequence is useful for treating includes acute brain injury resulting from stroke or traumatic brain injury and chronic disorders such as Huntington's chorea and schizophrenia. Furthermore, the presently described peptide sequence may further be useful in the treatment and amelioration of disorders associated with fear memory such as post-traumatic stress disorder.

Abstract: An apparatus for a test liquid includes an inlet device defining a chamber configured to receive the liquid, a preparation device defining a preparation chamber and including a preparation reagent to be reacted with the liquid, an analysis device defining an exposure chamber associated with the preparation chamber and including an analysis unit to be exposed to the prepared test liquid for indicating information on the test liquid, a housing defining a longitudinal axis, and a guiding device configured to guide the inlet device, the preparation device or the analysis device so as to limit the motion of the inlet device, the preparation device or the analysis device to a sequence of alternating rotational and axial movements, each axial movement of the inlet device, the preparation device or the analysis device requiring activation through a preceding rotational movement of the inlet device, the preparation device or the analysis device.

Abstract: The present invention relates to a method for evaluating the integrity of the cell wall of the bacteria present in a culture in the presence of an antibiotic acting on the bacterial cell wall which, from a practical point of view, allows quickly determining if a bacterium is sensitive or resistant to an antibiotic acting on the bacterial cell wall. Likewise, the present invention also relates to a lysis solution applicable in the preceding method, specifically affecting bacteria having the cell wall damaged by the action of an antibiotic acting on the bacterial cell wall, which allows distinguishing bacteria sensitive to said antibiotic from those resistant to said antibiotic.

Abstract: When an immunochromatography reagent composition containing a nonionic surfactant, an N,N-bis(2-hydroxyethyl)glycine buffer, and casein is used as a specimen treatment solution or developing solution in detecting a detection object in a specimen according to an immunochromatographic method, an immunochromatography reagent composition which suppresses a non-specific reaction; does not cause aggregation of antibody-immobilized colloidal gold; and has a high developing rate, in comparison with conventional technology which detects a detection object by using an immunochromatographic device; and a high-performance and highly-sensitivity immunochromatographic method and a detection kit capable of rapid, simple and easy virus detection, which use the immunochromatography reagent composition are provided.

Abstract: A system for reducing the incidence or severity of fungal infection of a plant, comprising a chemical fungicide component, which may be provided by foliar or root (soil or liquid nutrient) application, together with an antifungal plant defensin not in nature expressed in the plant being protected or expressed in lower amounts or in different tissues, provides synergistic improvement in protection against infection by a plant pathogenic fungus which is susceptible to the defensin and the fungicide. The fungicide can be a strobilurin or a triazole, and the defensin can be selected from a wide range of known defensins, for example, NaD1 and others, or it can be a chimeric defensin engineered for low toxicity to the plant. The defensin can be provided as a protein formulation, optionally together with the fungicide, or it can be provided by recombinant expression in the plant to be protected from fungal infection.

Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a AMPK activator to a subject in need thereof, wherein In certain embodiments, the AMPK activator is metformin or salt thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

Abstract: Systems, devices, and methods for accurately imaging chemiluminescence and other luminescence are disclosed. A compact, flat-bed scanner having a light-tight enclosure, one or more detector bars of linear charge-coupled device (CCD) or complementary metal oxide semiconductor (CMOS) imaging chips, and high working numerical aperture (NA) optics scans closely over a sample in one direction and then the opposite direction. Averages or other combinations of intensity readings for each pixel location (x, y) between the two or more passes are averaged together in order to compensate for luminescence that varies over time. On-chip pixel binning and multiple clock frequencies can be used to maximize the signal to noise ratio in a CCD-based scanner.

Abstract: The invention provides methods of treating a meiotic kinase-associated disease, preferably the meiotic kinase HSET, by administering an inhibitor of the meiotic kinase. Preferably, the disease is associated with the presence of supernumerary centrosomes, such as cancer. Methods of inhibiting the growth of a tumor cell by contacting the cell with an inhibitor of a meiotic kinase, preferably HSET, are also provided. Screening methods for identifying inhibitors of the meiotic kinase HSET are also provided. Methods of selecting subjects for treatment with an inhibitor of a meiotic kinase, such as HSET, are also provided.

Abstract: Provided is a method for measuring a color change of an oxidation-reduction indicator, which method is applicable to measurement of the cariogenic bacterial count and the like. A color change of an oxidation-reduction indicator is measured by a method for measuring a color change of an oxidation-reduction indicator, the method comprising reacting a test reagent with a test sample and measuring a color change, wherein the test reagent contains an oxidation-reduction indicator, an oxidation-reduction promoter, and a halogen salt.

Abstract: An immunological measurement is performed using anti-CTP antibody characterized by recognizing an antigenic determinant included in the polypeptide represented by amino acid numbers 118-132 of SEQ ID NO: 1, and reacting with native Cochlin-tomoprotein (CTP).

Abstract: The present invention relates to method of using a microfluidic chip for rapid nucleic acid hybridization, comprising: activating a porous substrate with positive charges; injecting a mixed solution of a test nucleic acid and a nucleic acid probe into the microfluidic chip for maintaining the test nucleic acid hybridized to the nucleic acid probe being absorbed to the periphery of the substrate; continuously washing the microfluidic chip with an anionic surfactant; and detecting the hybridization signals on the substrate after washing for a predetermined time; wherein the activation of the substrate with positive charges allows the test nucleic acid hybridized to the nucleic acid probe to form a micelle during washing and the diffusion of such from the periphery toward the center of the substrate to accelerate. Thus, it is possible to accomplish detection in a very short time for application of specific DNA complementary hybridization.

Abstract: The present invention relates to a method for measuring the activity of calcineurin in a biological sample wherein a kinase inhibitor is present in the assay reaction mix.

Abstract: Methods and kits for enzymes involved in post-translational modifications are provided. The methods employ elemental analysis, including ICP-MS. The methods allow for the convenient and accurate analysis of post-translation modifications of substrates by enzymes involved in post-translational modifications, including kinase and phosphatase enyzmes.

Abstract: Methods and kits for enzymes involved in post-translational modifications are provided. The methods employ elemental analysis, including ICP-MS. The methods allow for the convenient and accurate analysis of post-translation modifications of substrates by enzymes involved in post-translational modifications, including kinase and phosphatase enyzmes.

Abstract: A qualitative and quantitative hydrolase detection method includes providing a caged coelenterazine molecule having a detection molecule bonded between a first bonding site or a second bonding site of a coelenterazine molecule and a steric caging group; activating an uncaged coelenterazine molecule by cleaving the detection molecule in the caged coelenterazine molecule with a hydrolase enzyme; determining a light emission from a coelenterazine-activated bioluminescent enzyme reacting with the uncaged coelenterazine molecule activated in the presence of the hydrolase enzyme; and correlating the light emission for quantitatively and qualitatively determining the presence of the hydrolase enzyme.

Abstract: Provided are a cell analyzer, and a cell analysis method. A cell analyzer 1 includes a measurement device 2 for detecting information of each cell from a measurement specimen containing cells harvested from an epithelial tissue, and a data processing device 3 for determining appropriateness of the cell harvesting of parabasal cells and acquiring information related to canceration of the cell based on the information detected by the measurement device 2. The data processing device 3 displays on a display section a dialogue showing “cell harvesting inappropriate” when determined that the harvesting of parabasal cells is inappropriate.

Abstract: Provided is a method for simply and accurately measuring sphingomyelin in a sample, and a kit therefore. The method is a method for measuring sphingomyelin in a sample, comprising reacting the sample with a phospholipase D which does not react with sphingomyelin and lysophosphatidylcholine but reacts with phosphatidylcholine, a lysophospholipase or a monoglyceride lipase, and a choline oxidase, eliminating the formed hydrogen peroxide, reacting the resultant with a phospholipase D which does not react with glycerol-3-phosphorylcholine and free fatty acid but reacts with sphingomyelin, and a choline oxidase, and measuring the formed hydrogen peroxide.

Abstract: The present invention relates to the BAD pathway's influence on development, progression, chemo-sensitivity, and overall survival for multiple human cancers and its potential as a therapeutic target to increase chemo-sensitivity. BAD pathway expression was associated with the development and/or progression of breast, colon, and endometrial cancers, relapse-free survival from breast cancer, and overall survival from ovarian, colon, and brain cancers. Expression was also associated with in vitro sensitivity to a range of cytotoxic agents. pBAD levels were higher in cancer versus immortalized normal cells and chemo-resistant versus—sensitive cancer cells and associated with increased cell proliferation.

Abstract: A method for detecting a xerophilic microorganism is provided. The method comprises providing a sample to be tested, an aqueous diluent comprising about 1.0 to about 10.2 weight percent glycerol, and a thin film culture device comprising a cold water-reconstitutable medium to facilitate the growth of a microorganism. The method further comprises mixing the sample with the aqueous diluent to form an inoculum, contacting a predefined amount of the inoculum with the reconstitutable medium to form an inoculated thin film culture device, incubating the inoculated thin film culture device for a period of time, and detecting a presence or an absence of colony of a microorganism. Kits for detecting a xerophilic microorganism according to the method are also provided.

Abstract: The invention provides a variety of molecular tools for use in live-cell tracking of activities of biomolecules and in high-throughput drug screening.

Abstract: The present disclosure provides an optical biosensor including a complex including a porous support and an enzyme supported inside the pores of the porous support and a method for preparing the same. Since a dye does not flow but is concentrated in one place, the optical biosensor of the present disclosure has remarkably improved sensitivity. In addition, it is possible to carry out quantitative determination and qualitative analysis since color intensity increases with time.

Abstract: Tyrosine phosphorylation, regulated by protein tyrosine phosphatases (PTPs) and kinases (PTKs), is important in signaling pathways underlying tumorigenesis. A mutational analysis of the tyrosine phosphatase gene superfamily in human cancers identified 83 somatic mutations in six PTPs (PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, PTPN14), affecting 26% of colorectal cancers and a smaller fraction of lung, breast and gastric cancers. Fifteen mutations were nonsense, frameshift or splice site alterations predicted to result in truncated proteins lacking phosphatase activity. Five missense mutations in the most commonly altered PTP (PTPRT) were biochemically examined and found to reduce phosphatase activity. Expression of wild-type but not a mutant PTPRT in human cancer cells inhibited cell growth. These observations suggest that the tyrosine phosphatase genes are tumor suppressor genes, regulating cellular pathways that may be amenable to therapeutic intervention.

Abstract: An analytical device for analysis of chemical or biological samples, a method of using such a device, based on rotation of the device, integrated sample dosing and optical detection, and a system comprising such a device are disclosed. The analytical device comprises a device body having a liquid processing unit. The liquid processing unit comprises a mixing chamber for mixing a sample with a reagent, a sample dosing chamber for delivering a defined volume of the sample to the mixing chamber, and a reagent channel for delivering the reagent to be mixed with the sample, wherein the mixing chamber also serves as a detection chamber.

Abstract: In one aspect, the invention relates to a method for identifying a compound which modulates the activity of a voltage-gated protein. In certain embodiments, the voltage gate protein is a voltage-gated ion channel. In certain embodiments, the voltage-gated protein is a voltage sensitive phosphatase. In certain embodiments, the voltage-gated protein used in conjunction with the methods of the invention is modified to altered permeability or voltage sensitivity.

Abstract: The invention relates to a method for determining biochemical parameters of a body fluid, wherein a sample of said body fluid in the form of a droplet is transported through a channel of a microfluidic system using a carrier liquid, mixed with a reagent thus initiating a chemical reaction between the sample and the reagent, and the result of the chemical reaction is measured, preferably with a spectrophotometer, whereby the said biochemical parameters of the body fluid are determined, characterised in that the material used for fabrication of the microfluidic system and the said carrier liquid is pair of Teflon and Fluorinert HFE-7100.

Abstract: A boronic or borinic acid compound is used to inhibit the activity of a sulfenic acid-containing protein. Thus, a biologically-active sulfenic acid-containing protein is contacted with an activity-inhibiting effective amount of a boronic or borinic acid compound of Formula I or a salt, hydrate or solvate thereof, whose components are disclosed within, and that contact is maintained for a time sufficient to inhibit the biological activity of the protein.

Abstract: High affinity SIRP-? reagent are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for CD47 relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity SIRP? reagent, which blocks the physiological binding interaction between SIRP? and its ligand CD47.

Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.

Abstract: Methods of screening for candidate compounds capable of inhibiting activity of fyn in phosphorylating tau protein at Y394 or binding to fyn to inhibit interaction with tau protein at Y394, including determining whether, and optionally the extent, the candidate compounds have these capabilities under conditions where fyn has these capabilities in the absence of the candidate compound. Methods of screening for substances capable of promoting dephosphorylation of tau protein by a phosphatase at a site of tau protein including contacting a candidate substance, the tau protein and a phosphatase capable of dephosphorylating the tau protein under conditions where the phosphatase is capable of dephosphorylating the site in absence of the candidate substance, where the kinase is fyn; determining whether, and optionally the extent, the candidate substance promotes dephosphorylation of the tau protein at the site; and selecting the candidate substance which promotes dephosphorylation of the tau protein the sites.

Abstract: The present invention relates to a method for measuring the activity of calcineurin in a biological sample wherein a kinase inhibitor is present in the assay reaction mix.

Abstract: This invention provides a method for identifying allosteric modulators of a SHIP polypeptide, wherein said SHIP polypeptide is contacted with a test compound, and wherein said SHIP polypeptide comprises an allosteric site selected from the group consisting of a SHIP C2 domain and a SHIP PH domain.

Abstract: Methods and kits are disclosed for detecting microorganisms that produce glucose oxidase. The method includes providing a culture medium and a hydrogen peroxide indicating reagent comprising a chromogenic substrate that can provide a detectable chromogenic reaction indicating the presence of a microorganism that produces glucose oxidase, and additional methods are disclosed for differentiating microorganisms by the detection of an additional chromogenic reaction.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which includes a TENC1 (tensin like C1 domain-containing phosphatase) expression or activity suppressor, and, more specifically, relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which either suppresses the degradation of IRS-1 (insulin receptor substrate-1) or suppresses the phosphorylation of IRS-1 due to the PTPase activity of TENC1.

Abstract: Methods and kits for enzymes involved in post-translational modifications are provided. The methods employ elemental analysis, including ICP-MS.